Drugs / BCG
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06829823 | Nov 2025 → Nov 2026 expected | non-invasive bladder urothelial carcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06829823 ↗ |